SecBot SecBot
Biotech Drug Report Generated Aug 27, 2026

Photrexa

GKOS·GLAUKOS Corp
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on market since 2016
Why 4/10
Photrexa is an already-approved, marketed drug (since 2016) with no pending regulatory decision or hard binary catalyst in the next ~12 months. Its commercial trajectory is being superseded by Glaukos's next-gen Epioxa (approved Oct 2025). Per the impact score rubric, an approved drug with no pending regulatory decision scores 3-5; Photrexa lands at 4 because it remains a revenue contributor but is not the company's primary growth catalyst.
Actionable Insight NEUTRAL

Photrexa itself has no upcoming binary catalyst, it is an approved, marketed legacy product. Investors should instead focus on Glaukos's next-generation Epioxa (epi-on CXL, approved Oct 2025) and iDose TR glaucoma platform as the primary growth drivers. Monitor quarterly earnings for Epioxa adoption trends and the company's $690M 2026 revenue guidance execution.

Price Chart

Loading chart...

Executive Summary

Photrexa (riboflavin 5'-phosphate ophthalmic solution) is Glaukos Corporation's first-generation corneal collagen cross-linking (CXL) therapy, FDA-approved in 2016 as an orphan drug for progressive keratoconus and corneal ectasia. It is used with the KXL System in an "epithelium-off" procedure that requires removing the corneal surface layer. While Photrexa remains the only FDA-approved CXL therapy for keratoconus, its commercial importance is being eclipsed by Glaukos's next-generation product Epioxa (FDA-approved October 2025), a less-invasive "epithelium-on" version that does not require epithelium removal. For an investor, Photrexa is a mature, approved product with no pending binary catalyst, while the stock's key growth driver is the commercial ramp of Epioxa and the iDose TR glaucoma platform.

How It Works

Photrexa is a riboflavin (vitamin B2) solution used in a procedure called corneal collagen cross-linking (CXL). The riboflavin is applied to the eye and then activated by a specific UV light device (the KXL System). This activates the riboflavin to strengthen the collagen fibers in the cornea, the clear front part of the eye, halting the progression of keratoconus, a disease where the cornea progressively thins and bulges into a cone shape, causing vision loss. The original Photrexa procedure requires removing the thin outer layer of the cornea (epithelium) before treatment, which is why it's called "epi-off."

Trial Status

Photrexa was FDA-approved on April 15, 2016 (NDA 203324) as an orphan drug for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. It has been commercially marketed since 2016 and is the first-and-only FDA-approved corneal cross-linking therapy. The product is mature and established in the ophthalmic market.

The Two-Sided Case

▲ Bull Case4
Photrexa is the first-and-only FDA-approved corneal cross-linking therapy for keratoconus, with orphan drug exclusivity and a well-established market position since 2016
Glaukos has strong financials: $289M cash with no debt, 85% non-GAAP gross margins, and 20% 10-year revenue CAGR
Analyst consensus is strongly bullish on GKOS, 18 Buy/Strong Buy ratings vs. only 1 Sell, with a mean price target of $197 (8% upside from $180.57)
Large institutional holders including BlackRock ($1.33B), Vanguard ($464M), and PRIMECAP ($425M) demonstrate significant institutional confidence
▼ Bear Case4
Epioxa (approved Oct 2025) is a less-invasive 'epi-on' version that may cannibalize Photrexa sales as surgeons and patients migrate to the newer technology
Photrexa requires epithelium removal (epi-off), which is more invasive and uncomfortable for patients compared to the newer epi-on alternatives
The drug has been on market since 2016 with no new label expansion or regulatory catalyst ahead, making it a mature product with limited growth potential
Insider selling activity: CFO Alex Thurman sold ~$1.5M+ in stock in July 2026, and director Gilbert Kliman sold $475K in August 2026

Upcoming Catalysts

  • No upcoming binary catalyst for Photrexa specifically, it is a mature approved product
  • Glaukos quarterly earnings reports for overall company performance and Epioxa/iDose TR adoption
  • Epioxa commercial ramp (approved Oct 2025, commercially available March 2026) is the relevant catalyst for GKOS stock

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GLAUKOS Corp 8-K GKOS ·Originating report

Sources · 6

Hover a chip for the title
1 investors.glaukos.com2 accessdata.fda.gov3 businesswire.com4 pharmaceutical-technology.com5 glaukos.com6 sec.gov